Aprea Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Clinical Update

Core Insights - Aprea Therapeutics is making progress in its clinical trials, particularly with its WEE1 inhibitor APR-1051, showing early signs of disease control in patients with stable disease [1][3][4] - The company reported financial results for Q2 2025, indicating a decrease in operating loss compared to the same period in 2024, with cash and cash equivalents of $16.5 million as of June 30, 2025 [2][8][11] Clinical Development - The ongoing Phase 1 ACESOT-1051 trial of APR-1051 has shown that three patients achieved stable disease, including one patient with HPV-positive head and neck squamous cell carcinoma [3][7] - Aprea's ATR inhibitor ATRN-119 is also in clinical trials, with seven patients demonstrating stable disease and three showing significant tumor shrinkage at the 550 mg dose [3][11] - The company is expanding enrollment criteria for ACESOT-1051 to include patients with HPV+ tumors, with additional data expected in the second half of 2025 [7][11] Financial Performance - For Q2 2025, Aprea reported an operating loss of $3.4 million, a decrease from $3.8 million in Q2 2024, with R&D expenses at $1.9 million [11][17] - The company’s net loss for the quarter was $3.2 million, or $0.53 per share, compared to a net loss of $3.5 million, or $0.58 per share, in the same quarter of 2024 [11][17] - As of June 30, 2025, Aprea's total assets were $17.3 million, down from $24.0 million at the end of 2024 [14][15] Strategic Collaborations - Aprea has entered into a translational research collaboration with MD Anderson Cancer Center, which has yielded promising preclinical results for APR-1051 [5][9] - The collaboration aims to explore the potential of APR-1051 in combination with anti-PD-1 therapies for HPV+ head and neck cancer [5][9] Future Outlook - Aprea plans to submit an abstract to a major oncology conference and anticipates additional safety and efficacy data from its trials in the near future [7][11] - The company is also considering future arms of its trials to evaluate APR-1051 and ATRN-119 in combination with other therapies to address unmet medical needs [11][12]